SCHEMBL32664653

SCHEMBL32664653

CCCCCCCCc1cc(OCCO)ccc1S(N)(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDIA6 Q15084 1/20 0.50
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP1 P29466 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SLCO1B3 Q9NPD5 1/20 0.49
SLCO1B1 Q9Y6L6 1/20 0.49
CNR2 P34972 13/20 0.48
CNR1 P21554 4/20 0.48
TSHR P16473 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32664311 0.88 PDIA6 (0.50) PDIA6MEN1USP2ALDH1A1LMNA
SCHEMBL32664307 0.86 CNR2 (0.47) MEN1USP2ALDH1A1LMNACYP3A4
SCHEMBL29163148 0.83 HTR2A (0.43) PDIA6MAPK1TSHRCA12CA1
SCHEMBL32664548 0.83 HTR2A (0.43) PDIA6MAPK1TSHRCA12CA1
SCHEMBL29163149 0.81 MTNR1A (0.44) PDIA6MAPK1TSHRCA12CA1
SCHEMBL31145746 0.79 PDIA6 (0.46) PDIA6SMN1; SMN2TSHRCA12CA1
SCHEMBL9939329 0.79 CNR2 (0.72) MEN1CYP3A4KMT2ACNR2CNR1
SCHEMBL8013195 0.77 MEN1 (0.65) MEN1USP2ALDH1A1LMNACYP3A4
SCHEMBL8949684 0.77 PTPN11 (0.60) CNR2CNR1TSHR
SCHEMBL8027527 0.77 MEN1 (0.65) MEN1USP2ALDH1A1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 PDIA6 1650/4885MEN1 3316/4885USP2 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.